Sampo plc
25.9.2026 07:40:00 CEST | Globenewswire | Press release
Sampo completes its share buyback programme
Sampo completes its share buyback programme
Sampo plc, stock exchange release, 25 September 2026 at 8:40 am EEST
Sampo completes its share buyback programme
Sampo plc has completed its EUR 350 million share buyback programme, launched on 6 May 2026. The repurchases of shares began on 7 May 2026 and ended on 24 September 2026. During that period, Sampo repurchased 37,827,020 of its own A shares at an average price of EUR 9.24 per share. This corresponds to 1.42 per cent of all Sampo plc’s shares based on the share count prior to the start of this programme. The repurchase of own shares has reduced the company's unrestricted equity by approximately EUR 350 million.
The purpose of the buyback programme was to return excess capital to shareholders by reducing Sampo plc’s capital, as the repurchased shares will be cancelled. Following the cancellation, the total number of Sampo shares will be 2,617,847,806 shares, of which 2,616,847,806 will be A shares and 1,000,000 B shares.
Further information on share buybacks is available at www.sampo.com/sharebuyback.
SAMPO PLC
Investor Relations and Group Communications
For further information, please contact:
Mirko Hurmerinta
Interim Head of Investor Relations
tel. +358 10 516 0032
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG13.11.2026 19:30:00 CET | Press release
Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
Shufti Pro Limited13.11.2026 19:00:00 CET | Press release
Shufti Launches Patented On-Device AI Age Verification, Taking User Privacy Concerns Out of the Equation
XPENG13.11.2026 18:10:49 CET | Press release
XPENG Announces UK Pricing for New L03 and Flagship G9L, Starting from £32,990 and £64,990
Wolters Kluwer N.V.13.11.2026 18:00:00 CET | Press release
Wolters Kluwer to acquire AI-powered clinical decision support platform AgileMD
Novo Nordisk A/S13.11.2026 17:46:41 CET | Press release
FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom